Kamada

Plasma-derived Protein Therapeutics

Health Tech & Life Sciences
Public on TASE on Sep, 2005
Public on NASDAQ on Jun, 2008

Company Overview

Snapshot

Founded in December 1990 by David Tsur, Kamada operates with 201–500 employees. The company has raised a total of $150 million across 7 funding rounds from 2 investors.

Business overview

Kamada is a biopharmaceutical company specializing in plasma-derived protein therapeutics, leveraging its proprietary platform technology for the extraction and purification of proteins from human plasma. The company's product portfolio includes two FDA-approved products: GLASSIA for Alpha-1 Antitrypsin (AAT) deficiency, marketed in the United States through a partnership with Shire Plc, and KEDRAB, a rabies immune globulin distributed by Kedrion. Kamada also markets four additional plasma-derived pharmaceutical products globally and has a late-stage clinical pipeline for inhaled AAT and intravenous AAT for various conditions, serving the Health Tech & Life Sciences sector.

Strategic signal

In September 2024, Kamada announced the expansion of its plasma collection operations in Texas with the opening of a new site in Houston. This strategic move indicates the company's commitment to strengthening its supply chain and increasing its capacity for plasma-derived product manufacturing, signaling potential for future growth and market penetration in the biopharmaceutical industry.

Company Intelligence Q&A

What was a significant strategic transaction for Kamada in 2021?
In November 2021, Kamada announced a strategic transformational transaction aimed at positioning the company as a global leader in the plasma-derived hyperimmune market through the acquisition of a portfolio of four FDA-approved commercial products.
When did Kamada acquire Blood and Plasma Research, Inc.?
In February 2021, Kamada acquired an FDA-licensed plasma collection center from Blood and Plasma Research, Inc. in Texas, USA.
What was a key development regarding Kamada's GLASSIA supply in 2020?
In October 2020, Kamada provided an update on its 2021 GLASSIA supply to Takeda, indicating ongoing collaboration and product distribution.
When did Kamada expand its plasma collection operations in Texas?
In September 2024, Kamada announced the expansion of its plasma collection operations in Texas with the opening of a new site in Houston.

External links